Influenza: Addressing the Burden Through New Therapeutic Options

1.25 CME
$0 FEE
Influenza: Addressing the Burden Through New Therapeutic Options


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Genentech, Inc.

Activity Description

Influenza places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has caused between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. As such, there is an unmet need for better diagnostic and treatment modalities. Antiviral agents, with different targets and different mechanisms of action, provide multiple therapeutic options and hold promise in improving treatment effectiveness. In this monograph, expert faculty will discuss the diagnosis, epidemiology, and treatment of influenza.

Target Audience

The intended audience for the activity is infectious disease specialists and other health care professionals involved in the management of patients with influenza.

Learning Objective(s)

Upon successful completion of this educational activity, participants should be better able to:

  • Apply revised guidelines into practice regarding the diagnosis of influenza in the hospitalized patient to improve earlier detection and treatment.
  • Differentiate currently available treatments for influenza based on their efficacy, effect on duration of virus, and ability to improve outcomes for patients at normal and high risk for complications.
  • Incorporate therapeutic regimens into practice for prophylaxis, prevention, and treatment of influenza to reduce the duration of illness, viral shedding, and complications associated with the disease.

Activity Chair

Michael G. Ison, MD, MS, FIDSA, FAST
Professor, Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Medical Director, Transplant and Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Chicago, IL


William A. Fischer II, MD
Assistant Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
Institute of Global Health and Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, NC

Andrew T. Pavia, MD, FAAP, FIDSA
George and Esther Gross Presidential Professor
Chief, Division of Pediatric Infectious Diseases
University of Utah
Director, Hospital Epidemiology Program
Primary Children's Hospital
Salt Lake City, UT

Medical Writer

Valerie Zimmerman, PhD


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 1, 2020 through January 1, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of the 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate. 


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. 

The articles in the monograph were composed by medical writer Valerie Zimmerman, PhD, based on the presentations of Drs. Ison, Fischer, and Pavia during a live symposium on October 4, 2019.

Activity Chair and Faculty report the following relationship(s)

William A. Fischer II, MD
Speaker Honoraria: Genentech

Michael G. Ison, MD, MS, FIDSA, FAST
Royalty: UpToDate
Consulting Fee: Celltrion, Genentech/Roche, Janssen, Seqirus, Shionogi, Toyama/MediVector, Vir Biotechnology
Contracted Research: Beckman Coulter, Cepheid, Chimerix, Emergent BioScience, Gilead, Janssen, Shire
Data Safety & Monitoring Board: GlaxoSmithKline, Shionogi

Andrew T. Pavia, MD, FAAP, FIDSA
Royalty: Antimicrobial Therapy
Consulting Fee: Genentech, Merck, Seqirus

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Medical Writer reports the following relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at